Journal of Applied Pharmacy
ISSN: 1920-4159
OPEN ACCESS Freely available online
Perspective

Sialic acid Applications in the Drug Delivery Systems

Rebacca Smith*

Department of Pharmacy, Belfast University, United Kingdom (UK)

PERSPECTIVE

The properties of modified biomaterial are gaining more and more importance in drug transport systems. Sialic Acid (SA) serves as endogenous substances, which are non-immunogenic and biodegradable. At the same time, Salic acid modification of the drugs/carriers can increase the uptake of tumor cell and retention in brain; Poly sialic acid modification can reduce the immunogenicity of the proteins or polypeptides and increase circulation time of the modified drugs/carriers in the blood, thus achieving active targeting effect. These properties offer a variety of opportunities for applications in drug delivery systems. This article summarizes the biological functions of Salic acid and presents the technologies of Salic acid modified small molecule drugs, proteins and carriers in drug delivery systems.

Nature sialic corrosive is established fundamentally by 9-carbons 3-deoxy-ulosonic acids. This saccharide moiety appended to starch chains of glycolipids and glycoproteins assumes a significant part in numerous significant organic events. Curiously, it has been discovered that sialic acid is a notable ligand for selectin, which is known to have a close relationship with growth metastases. Attributable to its adjustment of cell–cell connections among leukocytes, platelets, endothelial cells and growth cells, selectin is liable for cancer metastasis. Salic acid fills in as endogenous substances that can explicitly tie to selectin. Consequently, the use of sialic acid -adjusted transporters in malignant growth designated treatment has a specific importance.

In the historical backdrop of Drug Delivery systems, transporter and medication particles PEGylated (PEGylation) innovation is viewed as an achievement. PEGylation nanoparticles can successfully lessen the macrophage take-up in vitro, drag out the course half-life in vivo and decline the gathering of nanoparticles in liver and spleen. PEGylation can likewise work on the aggregation of nanoparticles in cancer tissue by applying the upgraded penetrability and maintenance (EPR) impact that is the reason for conveying the macromolecular medications to the site of strong growths specifically. Notwithstanding, the PEG layer brings the accompanying three issues. Cellular take-up impeded marvel. The "cloud" of hydrophilic steric boundary assumes an essential part in drawing out the home time yet it can significantly stifle their communication with cells. Accelerated blood freedom marvel at the point when rehashed infusion, PEGylated transporters plentifully produce hostile to PEG IgM and subsequently upgrade blood leeway in light of against PEG IgM intervening supplement actuation under specific conditions. The wonder is classified "sped up blood leeway (ABC) Security. Stake is hard to debase in the body and gathers in lysosomes, which can incite harmfulness and surprisingly a modest quantity of PEG oxidation items in vivo is additionally unsafe. So sped up blood leeway wonder and the gathering of PEG might carry genuinely genuine results to the body.

Sialic acid has shown specific advantages of tumour targeting, cancer inhibition and stealth properties in the drug delivery systems. At the same time, Salic acid is non-immunogenic, biocompatible and biodegradable, which can reduce or eliminate So sped up blood leeway phenomenon of PEGylation preparation to some extent. However, Salic acid receptors lie in other normal cells, tissues and organs that will bring undesired problems. Hence, it is of great significance to find Salic acid/Poly salic acid appropriate modification sites, change drugs/carriers linkage and optimize salic acid or poly salic acid modified density in the drug delivery systems.

Correspondence to: Rebacca Smith, Department of Pharmacy, Belfast University, Uinted Kingdom (UK), E-mail: rebaccas@gmail.com

Received: September 09, 2021; **Accepted:** September 23, 2021; **Published:** September 30, 2021

Citation: Smith R (2021) Sialic acid Applications in the Drug Delivery Systems. J Appl Pharm 13:315.